source
- FDA panel backs compounding of epitalon, rejects emideltide in narrow voteThe FDA advisory committee voted to allow compounding pharmacies to produce the peptide epitalon, while narrowly voting against allowing the production of emideltide. The decision follows the pane…
- Ipsen's Bylvay fails Phase 3 trial in children with biliary atresiaIpsen announced that its experimental therapy Bylvay did not meet its primary endpoint in a Phase 3 trial targeting biliary atresia in infants. Biliary atresia is a rare pediatric liver disorder i…